Guidelines on haemovigilance of post-transfusional iron overload

Blood Transfusion

Volumn 11, Issue 1, 2013, Pages 128-139

  Remacha, Ángel ^a   Sanz, Cristina ^b   Contreras, Enric ^c   De Heredia, Cristina Díaz ^d   Grifols, Joan Ramón ^e   Lozano, Montserrat ^f   Nuñez, Guillermo Martín ^g   Salinas, Ramón ^h   Corral, Mercedes ⁱ   Villegas, Ana ^j  

^a HOSPITAL VIRGEN DE LA SALUD   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^f HOSPITAL DONOSTIA   (Spain)

^g HOSPITAL VIRGEN DEL PUERTO   (Spain)

^h HOSPITAL MÚTUA DE TERRASSA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^j HOSPITAL CLÍNICO SAN CARLOS   (Spain)

more..

Author keywords

Haemosiderosis; Haemovigilance; Iron overload; Transfusion

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN; HEPCIDIN; IRON; TRANSFERRIN;

ACUTE LEUKEMIA; AGRANULOCYTOSIS; ANDROGEN RELEASE; ARTHRALGIA; ARTHROPATHY; BLOOD SAFETY; BLOOD TRANSFUSION; BONE MARROW APLASIA; CATARACT; CELL DAMAGE; CELL HYPERPLASIA; CHELATION THERAPY; DIABETES MELLITUS; DISEASE FREE SURVIVAL; DISEASE SEVERITY; ERYTHROCYTE; FANCONI ANEMIA; FERRITIN BLOOD LEVEL; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GROWTH DISORDER; GROWTH HORMONE DEFICIENCY; HEARING IMPAIRMENT; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CONDUCTION DISTURBANCE; HEART VENTRICLE ARRHYTHMIA; HEMOCHROMATOSIS; HEMOLYTIC ANEMIA; HEMOSIDEROSIS; HEREDITARY SPHEROCYTOSIS; HUMAN; HYPERTRANSAMINASEMIA; HYPOGONADOTROPIC HYPOGONADISM; HYPOPARATHYROIDISM; HYPOTHYROIDISM; INBORN ERROR OF METABOLISM; INSULIN RESISTANCE; IRON ABSORPTION; IRON OVERLOAD; KIDNEY DISEASE; LIVER FIBROSIS; LYMPHOMA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PANCREAS ISLET BETA CELL; PROTEIN BLOOD LEVEL; RASH; REVIEW; RISK FACTOR; SEXUAL MATURATION; SICKLE CELL ANEMIA; SIDE EFFECT; SURVIVAL RATE; THALASSEMIA MAJOR; VISUAL DISORDER; ZINC DEFICIENCY;

FEMALE; GUIDELINE ADHERENCE; HUMANS; IRON OVERLOAD; MALE; SPAIN;

EID: 84872250913     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2012.0114-11     Document Type: Review

References (58)

1. Cazzola M, Malcovati L. Myelodysplastic syndromes - coping with ineffective hematopoiesis. N Engl J Med 2005; 352: 536-8. (Pubitemid 40204666)
2. Cohen AR, Porter JB. Consequences of iron-mediated toxicity. Cambridge, UK: Cambridge University Press, 2001.
3. Remacha AF, Arrizabalaga B, Del Canizo C, et al. Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements. Ann Hematol 2010; 89: 147-54.
4. Gatterman MI, Hansen DT. Development of chiropractic nomenclature through consensus. J Manipulative Physiol Ther 1994; 17: 302-9. (Pubitemid 24188448)
5. Shander A, Sazama K. Clinical consequences of iron overload from chronic red blood cell transfusions, its diagnosis, and its management by chelation therapy. Transfusion 2010; 50: 1144-55.
6. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994; 331: 567-73. (Pubitemid 24265698)
7. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994; 331: 574-8. (Pubitemid 24265699)
8. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007; 25: 3503-10. (Pubitemid 47315575)
9. Pereira A, Nomdedeu M, Aguilar JL, et al. Transfusion intensity, not the cumulative red blood cell transfusion burden, determines the prognosis of patients with myelodysplastic syndrome on chronic transfusion support. Am J Hematol 2011; 86: 245-50.
10. Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005; 23: 7594-603. (Pubitemid 46291823)
11. Delea TE, Hagiwara M, Phatak PD. Retrospective study of the association between transfusion frequency and potential complications of iron overload in patients with myelodysplastic syndrome and other acquired hematopoietic disorders. Curr Med Res Opin 2009; 25: 139-47.
12. Koreth J, Antin JH. Iron overload in hematologic malignancies and outcome of allogeneic hematopoietic stem cell transplantation. Haematologica 2010; 95: 364-6.
13. Alessandrino EP, Della Porta MG, Bacigalupo A, et al. Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. Haematologica 2010; 95: 476-84.
14. Altes A, Remacha AF, Sarda P, et al. Early clinical impact of iron overload in stem cell transplantation. A prospective study. Ann Hematol 2007; 86: 443-7. (Pubitemid 46655483)
15. Armand P, Kim HT, Cutler CS, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007; 109: 4586-8. (Pubitemid 46743431)
16. Mahindra A, Sobecks R, Rybicki L, et al. Elevated pretransplant serum ferritin is associated with inferior survival following nonmyeloablative allogeneic transplantation. Bone Marrow Transplant 2009; 44: 767-8.
17. Borgna-Pignatti C. The life of patients with thalassemia major. Haematologica 2010; 95: 345-8.
18. Shander A, Cappellini MD, Goodnough LT. Iron overload and toxicity: the hidden risk of multiple blood transfusions. Vox Sang 2009; 97: 185-97.
19. Porter JB. Optimizing iron chelation strategies in beta-thalassaemia major. Blood Rev 2009; 23 (Suppl 1): S3-7.
20. Inati A. Recent advances in improving the management of sickle cell disease. Blood Rev 2009; 23 (Suppl 1): S9-13.
21. de Witte T. The role of iron in patients after bone marrow transplantation. Blood Rev 2008; 22 (Suppl 2): S22-8.
22. Litzow MR, Tarima S, Perez WS, et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 2010; 115: 1850-7.
23. Majhail NS, Lazarus HM, Burns LJ. Iron overload in hematopoietic cell transplantation. Bone Marrow Transplant 2008; 41: 997-1003. (Pubitemid 352034174)
24. th Annual Meeting of the European Group for Blood and Marrow Transplantation. Available at: http://registration.akm.ch/einsicht.php?XNABSTRACT-ID= 123469&XNSPRACHE-ID=2&XNKONGRESS-ID=138&XNMASKEN-ID=900. Accessed on 15/06/2011.
25. Bennett JM. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol 2008; 83: 858-61.
26. Bowen D, Culligan D, Jowitt S, et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 2003; 120: 187-200. (Pubitemid 36194166)
27. Takatoku M, Uchiyama T, Okamoto S, et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol 2007; 78: 487-94. (Pubitemid 46753591)
28. Wells RA, Leber B, Buckstein R, et al. Iron overload in myelodysplastic syndromes: a Canadian consensus guideline. Leuk Res 2008; 32: 1338-53.
29. Zamora C, Díaz M, Cid J. Características clínicas de la población con dependencia transfusional crónica en España. Resultados del Estudio 20CH. In: XXI Congreso de la SETS. Tarragona, Spain, 2010.
30. Jensen PD. Evaluation of iron overload. Br J Haematol 2004; 124: 697-711.
31. Taher A, Cappellini MD, Vichinsky E, et al. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol 2009; 147: 752-9.
32. nd Edition (http://www.thalassaemia.org. cy/pdf/Guidelines-2nd-revised-edition-EN.pdf). In: Thalassemia International Federation, 2008. Accessed on 15/11/2011.
33. Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000; 343: 327-31. (Pubitemid 30616698)
34. St Pierre TG, Clark PR, Chua-anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005; 105: 855-61. (Pubitemid 40070775)
35. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001; 22: 2171-9. (Pubitemid 33139463)
36. Anderson LJ, Westwood MA, Holden S, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2*cardiovascular magnetic resonance. Br J Haematol 2004; 127: 348-55. (Pubitemid 39468951)
37. Pennell DJ. T2* magnetic resonance and myocardial iron in thalassemia. Ann N Y Acad Sci 2005; 1054: 373-8. (Pubitemid 43031044)
38. Davis BA, O'Sullivan C, Jarritt PH et al. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood 2004; 104: 263-9. (Pubitemid 38879867)
39. Kirk P, Roughton M, Porter JB et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 2009; 120: 1961-8.
40. Directiva 2002/98/CE del Parlamento Europeo y del Consejo de 27 de enero de 2003 por la que se establecen normas de calidad y de seguridad para la extracción, verificación, tratamiento, almacenamiento y distribución de sangre humana y sus componentes y por la que se modifica la Directiva 2001/83/CE (http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri= OJ:L:2003:033:0030:0040:ES:PDF). Accessed on 15/11/2011.
41. Real Decreto 1088/2005, de 16 de septiembre, por el que se establecen los requisitos técnicos y condiciones mínimas de la hemodonación y de los centros y servicios de transfusión (http://www.boe.es/boe/dias/2005/09/20/pdfs/A31288-31304.pdf). Accessed on 15/11/2011.
42. Orden SCO/322/2007, de 9 de febrero, por la que se establecen los requisitos de trazabilidad y de notificación de reacciones y efectos adversos graves de la sangre y de los componentes sanguíneos (http://www.boe.es/boe/dias/2007/02/17/pdfs/A07010-07016.pdf). Accessed on 15/11/2011.
43. Arrizabalaga B, del Cañizo C, Remacha A et al. Guía clínica de quelación del paciente con síndrome mielodisplásico. Hematologia 2008; 93: 1-10.
44. Bronspiegel-Weintrob N, Olivieri NF, Tyler B et al. Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassemia major. N Engl J Med 1990; 323: 713-9. (Pubitemid 20288940)
45. Hershko C. Oral iron chelators: new opportunities and new dilemmas. Haematologica 2006; 91: 1307-12. (Pubitemid 44569802)
46. Angelucci E, Barosi G, Camaschella C, et al. Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica 2008; 93: 741-52. (Pubitemid 351669315)
47. Anderson LJ, Wonke B, Prescott E, et al. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002; 360: 516-20. (Pubitemid 35232104)
48. Maggio A, D'Amico G, Morabito A et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis 2002; 28: 196-208. (Pubitemid 34743754)
49. Olivier NF, Brittenham GM. Final result of the randomized trial of deferiprone (L1) and deferoxamine (DFO). Blood (ASH Annual Meeting Abstracts) 1997; 90: Abstract 264.
50. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006; 107: 3738-44.
51. Tanner MA, Galanello R, Dessi C et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007; 115: 1876-84. (Pubitemid 46598901)
52. Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003; 102: 17-24. (Pubitemid 36759630)
53. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006; 107: 3455-62.
54. Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol 2008; 80: 168-76.
55. th ASH Annual Meeting of the American Society of Hematology. San Francisco, California, EEUU, 2008: Abstract 640.
56. Rose C, Brechignac S, Vassilief D, et al. Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients. A prospective analysis by the GFM. Blood (ASH Annual Meeting Abstracts) 2007; 110: 249.
57. Porter JB. Concepts and goals in the management of transfusional iron overload. Am J Hematol 2007; 82: 1136-9. (Pubitemid 350221244)
58. List AF, Baer MR, Steensma DP, et al. Two-year analysis of efficacy and safety of deferasirox (Exjade®) treatment in myelodysplastic syndrome patients enrolled in the US03 study. Blood (ASH Annual Meeting Abstracts) 2009; 114: 3829.